Table 2.
Wang et al. (2007b)* | This study | |
---|---|---|
AAV-micro-dystrophin | ||
Construct | Canine ΔR4-R23/ΔC | Canine R16-17/H3/ΔC |
Promoter | CMV | CMV |
AAV serotype | Type 6 | Type 6, Y445F tyrosine mutant |
Viral dose (per muscle) | 1×1011 v.g. | 2.85×1012 v.g. |
Cyclosporin | ||
Dose | 10 mg/kg/d, oral | 10–20 mg/kg/d, oral |
Blood level | 100–350 ng/mL | 400–600 ng/mL |
Duration | −2 day to 18 weeks | −7 day to 4 weeks |
Mycophenolate | ||
Dose | 15 mg/kg/d, subcutaneous | 40 mg/kg/d, oral |
Duration | −2 day to 18 weeks | −7 day to 4 weeks |
Anti-thymocyte globulin | ||
Dose | 1 mg/kg/d, subcutaneous | Not used |
Duration | −2 day to 2 days | |
Longest time point | ||
After AAV injection | 30 weeks | 22 weeks |
After cessation of immune suppression | 12 weeks | 18 weeks |
This is different from the protocol used for human micro-dystrophin vector (depicted in Fig 1).